eCite Digital Repository

Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus

Citation

Corbould, A and Swinton, F and Radford, A and Campbell, J and McBeath, S and Dennis, A, Fasting blood glucose predicts response to extended-release metformin in gestational diabetes mellitus, Australian and New Zealand Journal of Obstetrics and Gynaecology, 53, (2) pp. 125-129. ISSN 0004-8666 (2013) [Refereed Article]

Copyright Statement

Copyright 2012 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists

DOI: doi:10.1111/ajo.12018

Abstract

Background: Metformin is increasingly accepted as an alternative to insulin therapy in gestational diabetes mellitus (GDM). The Metformin in Gestational Diabetes (MiG) trial reported similar pregnancy outcomes for metformin versus insulin; however, supplemental insulin was required in 46% of women on metformin.

Aims: We aimed to identify predictors of response to metformin monotherapy in women with GDM attending a general hospital antenatal clinic. Methods We offered extended-release metformin to women diagnosed with GDM (ADIPS 1998 criteria) at ≥24 weeks of gestation. If glucose targets were not achieved (≤5.0 mmol/L fasting, ≤6.7 mmol/L two-h post-meal), women were changed to insulin. We carried out an audit to determine characteristics of metformin responders versus nonresponders.

Results: Twenty-five women chose initial metformin therapy; 16 (64%) achieved satisfactory glycaemic control (responders). Nine women (36%) were changed to insulin: seven due to inadequate control (nonresponders) and two had metformin intolerance. Fasting glucose at oral glucose tolerance test (OGTT) was significantly lower in metformin responders versus nonresponders; two-h glucose and BMI did not differ. Ninety-three percent of women with fasting glucose ≤5.2 mmol/L responded to metformin: conversely, at fasting glucose >5.2 mmol/L, 33% responded (P = 0.005). Neonatal outcomes were similar in metformin responders and nonresponders, women who chose initial insulin therapy (n = 25), or were diet-controlled (n = 21).

Conclusions: In women with GDM, fasting glucose on OGTT predicted response to metformin: at fasting glucose ≤5.2 mmol/L, the probability of response was 93%. Antenatal clinics should determine locally relevant predictors of response to metformin in women with GDM.

Item Details

Item Type:Refereed Article
Keywords:body mass index, diabetes gestational, glucose tolerance test, insulin, metformin
Research Division:Medical and Health Sciences
Research Group:Medical Biochemistry and Metabolomics
Research Field:Medical Biochemistry: Carbohydrates
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Diabetes
Author:Corbould, A (Dr Anne Corbould)
Author:Dennis, A (Associate Professor Amanda Dennis)
ID Code:91964
Year Published:2013
Web of Science® Times Cited:8
Deposited By:Medicine (Discipline)
Deposited On:2014-06-04
Last Modified:2014-08-05
Downloads:0

Repository Staff Only: item control page